Hostname: page-component-848d4c4894-pjpqr Total loading time: 0 Render date: 2024-06-22T01:34:57.041Z Has data issue: false hasContentIssue false
  • English
  • Français

Impact of Drug Tolerability on the Selection of Antidepressant Treatment in Patients With Major Depressive Disorder

Published online by Cambridge University Press:  07 November 2014

Lawrence D. Ginsberg
Lawrence D. Ginsberg*
Affiliation:
Dr. Ginsberg is president and CEO of Red Oak Psychiatry Associates, PA, in Houston, Texas.
*
Lawrence D. Ginsberg, MD, Red Oak Psychiatry Associates, PA, 17115 Red Oak Drive, Suite 109, Houston, TX 77090; Tel: 281-893-4111; Fax: 281-893-8082; E-mail: larrydg@earthlink.net.
Get access Rights & Permissions [Opens in a new window]

Abstract

Despite significant progress in the development of antidepressant therapies, tolerability remains an important factor associated with the selection of appropriate antidepressant treatment. Side effects commonly reported by depressed patients taking antidepressants include weight gain, sexual dysfunction, and gastrointestinal effects. Tolerability issues associated with antidepressants can negatively impact treatment outcomes for patients with major depressive disorder. In addition, a drug's tolerability profile substantially influences a physician's choice of specific antidepressant therapy. Despite the availability of many antidepressants, empirical clinical evidence to guide physicians in making the best choice is limited and not always clear. Thus, it is key for clinicians to understand the short- and long-term outcomes and side effect profiles of the available antidepressants.

Type
Research Article
Information
CNS Spectrums , Volume 14 , Issue S12 , 2009 , pp. 8 - 14
Copyright
Copyright © Cambridge University Press 2009

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Papakostas, GI. Tolerability of modern antidepressants. J Clin Psychiatry. 2008;69(suppl E1):8–13.Google Scholar
2.Stahl, SM, Grady, MM, Moret, C, Briley, M. SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectr. 2005;10(9):732–747.Google Scholar
3.Gartlehner, G, Thieda, P, Hansen, RA, et al.Comparative risk for harms of second-generation antidepressants: a systematic review and meta-analysis. Drug Saf. 2008;31(10):851–865.Google Scholar
4.Thase, ME, Haight, BR, Richard, N, et al.Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials. J Clin Psychiatry. 2005;66(8):974–981.CrossRefGoogle ScholarPubMed
5.Hu, XH, Bull, SA, Hunkeler, EM, et al.Incidence and duration of side effects and those rated as bothersome with selective serotonin reuptake inhibitor treatment for depression: patient report versus physician estimate. J Clin Psychiatry. 2004;65(7):959–965.Google Scholar
6.Zimmerman, M, Posternak, M, Friedman, M, et al.Which factors influence psychiatrists' selection of antidepressants? Am J Psychiatry. 2004;161(7):1285–1289.Google Scholar
7.Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association. Am J Psychiatry. 2000;157(4 suppl):1–45.Google Scholar
8.Geddes, JR, Carney, SM, Davies, C, et al.Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet. 2003;361(9358):653–661.Google Scholar
9.Melfi, CA, Chawla, AJ, Croghan, TW, Hanna, MP, Kennedy, S, Sredl, K. The effects of adherence to antidepressant treatment guidelines on relapse and recurrence of depression. Arch Gen Psychiatry. 1998;55(12):1128–1132.Google Scholar
10.Melartin, TK, Rytsälä, HJ, Leskelä, US, Lestelä-Mielonen, PS, Sokero, TP, Isometsä, ET. Continuity is the main challenge in treating major depressive disorder in psychiatric care. J Clin Psychiatry. 2005;66(2):220–227.CrossRefGoogle ScholarPubMed
11.Kornstein, SG, Bose, A, Li, D, Saikali, KG, Gandhi, C. Escitalopram maintenance treatment for prevention of recurrent depression: a randomized, placebo-controlled trial. J Clin Psychiatry. 2006;67(11):1767–1775.Google Scholar
12.Nelson, JC, Lu Pritchett, Y, Martynov, O, Yu, JY, Mallinckrodt, CH, Detke, MJ. The safety and tolerability of duloxetine compared with paroxetine and placebo: a pooled analysis of 4 clinical trials. Prim Care Companion J Clin Psychiatry. 2006;8(4):212–219.Google ScholarPubMed
13.Fava, M, Judge, R, Hoog, SL, Nilsson, ME, Koke, SC. Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment. J Clin Psychiatry. 2000;61(11):863–867.Google Scholar
14.Pigott, TA, Prakash, A, Arnold, LM, Aaronson, ST, Mallinckrodt, CH, Wohlreich, MM. Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder. Curr Med Res Opin. 2007;23(6):1303–1318.Google Scholar
15.Wise, TN, Perahia, DG, Pangallo, BA, Losin, WG, Wiltse, CG. Effects of the antidepressant duloxetine on body weight: analyses of 10 clinical studies. Prim Care Companion J Clin Psychiatry. 2006;8(5):269–278.Google Scholar
16.Keller, MB, Trivedi, MH, Thase, ME, et al.The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) study: outcomes from the acute and continuation phases. Biol Psychiatry. 2007;62(12):1371–1379.CrossRefGoogle ScholarPubMed
17.Boyer, P, Montgomery, S, Lepola, U, et al.Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial. Int Clin Psychopharmacol. 2008;23(5):243–253.Google Scholar
18.Lieberman, DZ, Montgomery, SA, Tourian, KA, et al.A pooled analysis of two placebo-controlled trials of desvenlafaxine in major depressive disorder. Int Clin Psychopharmacol. 2008;23(4):188–197.Google Scholar
19.Liebowitz, M, Yeung, PP, Entsuah, R. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in adult outpatients with major depressive disorder. J Clin Psychiatry. 2007;68(11):1663–1672.Google Scholar
20.Liebowitz, M, Manley, AL, Padmanabhan, SK, Ganguly, R, Tummala, R, Tourian, KA. Efficacy, safety, and tolerability of desvenlafaxine 50 mg/d and 100 mg/d in outpatients with major depressive disorder. Curr Med Res Opin. 2008;24(7):1877–1890.Google Scholar
21.Clayton, AH, Pradko, JF, Croft, HA, et al.Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry. 2002;63(4):357–366.Google Scholar
22.Rosen, RC, Lane, RM, Menza, M. Effects of SSRIs on sexual function: a critical review. J Clin Psychopharmacol. 1999;19(1):67–85.CrossRefGoogle ScholarPubMed
23.Behnke, K, Sogaard, J, Martin, S, et al.Mirtazapine orally disintegrating tablet versus sertraline: a prospective onset of action study. J Clin Psychopharmacol. 2003;23(4):358–364.Google Scholar
24.Wade, A, Crawford, GM, Angus, M, Wilson, R, Hamilton, L. A randomized, double-blind, 24-week study comparing the efficacy and tolerability of mirtazapine and paroxetine in depressed patients in primary care. Int Clin Psychopharmacol. 2003;18(3):133–141.Google Scholar
25.Versiani, M, Moreno, R, Ramakers-van Moorsel, CJ, Schutte, AJ, and the Comparative Efficacy Antidepressants Study Group. Comparison of the effects of mirtazapine and fluoxetine in severely depressed patients. CNS Drugs. 2005;19(2):137–146.Google Scholar
26.Mehtonen, OP, Sogaard, J, Roponen, P, Behnke, K. Randomized, double-blind comparison of venlafaxine and sertraline in outpatients with major depressive disorder. Venlafaxine 631 Study Group. J Clin Psychiatry. 2000;61(2):95–100.Google Scholar
27.Goldstein, DJ, Mallinckrodt, C, Lu, Y, Demitrack, MA. Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial. J Clin Psychiatry. 2002;63(3):225–231.Google Scholar
28.Clayton, A, Kornstein, S, Prakash, A, Mallinckrodt, C, Wohlreich, M. Changes in sexual functioning associated with duloxetine, escitalopram, and placebo in the treatment of patients with major depressive disorder. J Sex Med. 2007;4(4 Pt 1):917–929.Google Scholar
29.Nelson, JC. Safety and tolerability of the new antidepressants. J Clin Psychiatry. 1997;58(suppl 6):26–31.Google ScholarPubMed
30.Ferguson, JM. SSRI antidepressant medications: adverse effects and tolerability. Prim Care Companion J Clin Psychiatry. 2001;3(1):22–27.Google Scholar
31.Mucci, M. Reboxetine: a review of antidepressant tolerability. J Psychopharmacol. 1997;11(4 suppl):33–37.Google Scholar
32.Westenberg, HG, Sandner, C. Tolerability and safety of fluvoxamine and other antidepressants. Int J Clin Pract. 2006;60(4):482–491.Google Scholar
33. Effexor XR [package insert]. Philadelphia, PA: Wyeth Pharmaceuticals; 2008.Google Scholar
34. Cymbalta [package insert]. Indianapolis, IN: Eli Lilly and Company; 2007.Google Scholar
35. Pristiq [package insert]. Philadelphia, PA: Wyeth Pharmaceuticals; 2008.Google Scholar
36. Ixel [package insert]. France: Pierre Fabre Medicaments; 2003.Google Scholar